Yuttiwat Vorakunthada, MD
Pulmonary Disease · Dover, NHNPI 1851742514
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,201 of the $1,908 with a category attached, or 62.9%. 11 manufacturers reported payments, led by Olympus Corporation Of The Americas at 28.6% of the total. Reporting peaked in 2022 at $612 and has fallen 66.9% since, to $202 in 2025.
Across 31 payments — averaging $61.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus Corporation Of The Americas$546
- Actelion Pharmaceuticals US, Inc.$479
- United Therapeutics Corporation$309
- Boehringer Ingelheim$188
- BD$186
- Inspire Medical Systems, Inc.$76
- plus $124 from 5 others
What the payments were for
- Speaking & faculty fees$18610%
- Travel & lodging$52127%
- Food & beverage$1,20163%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus Corporation Of The Americas | 8 | $546 |
| Actelion Pharmaceuticals US, Inc. | 4 | $479 |
| United Therapeutics Corporation | 3 | $309 |
| Boehringer Ingelheim | 3 | $188 |
| BD | 6 | $186 |
| Inspire Medical Systems, Inc. | 1 | $76 |
| GSK | 1 | $36 |
| AstraZeneca | 2 | $29 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,908 in reported general payments places this provider in the 75th percentile of 78 pulmonary disease providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 198 | $198,023 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 73 | $43,398 |
| Breo ElliptaFluticasone/Vilanterol | 66 | $37,891 |
| Spiriva RespimatTiotropium Bromide | 54 | $31,536 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $24,155 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 48 | $23,677 |
| Advair HfaFluticasone Propion/Salmeterol | 50 | $20,013 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $11,528 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 19 | $10,853 |
| EliquisApixaban | 12 | $7,582 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 18 | $6,782 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $6,628 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 37 | $6,245 |
| BreynaBudesonide/Formoterol Fumarate | 29 | $4,856 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 166 | $3,876 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $36 | $289,609364 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $188 | $66,066121 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $29 | $42,46588 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 78 pulmonary disease providers in New Hampshire.
Other pulmonary disease in Dover
- Bianca MonteiroDover$43K
- David ReevesDover$662
- Vinia Madonna MendozaDover$594
- Dhruv DesaiDover$138
- Syed Mudassar NaqshbandiDover$59
- Manuel de AguirreDover$31
- Donald MahlerLebanon$411K
- Jeffrey StewartLebanon$30K
- Erik SwensonLebanon$29K
- Elliot BackerLebanon$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.